< previous page page_169 next page >

Page 169
6
Novel Drug Delivery Systems
Bret Berner
Cygnus, Inc.
Redwood City, California
Agis Kydonieus
ConvaTec, A Bristol-Myers Squibb Company
Princeton, New Jersey
6fb6ffc4153cdc534470145c4eef46f0.gif
I. Introduction
170
6fb6ffc4153cdc534470145c4eef46f0.gif
A. Patient Compliance
170
6fb6ffc4153cdc534470145c4eef46f0.gif
B. Reduction of Side Effect Profile
172
6fb6ffc4153cdc534470145c4eef46f0.gif
II. Routes of Administration
172
6fb6ffc4153cdc534470145c4eef46f0.gif
A. The GI Tract
173
6fb6ffc4153cdc534470145c4eef46f0.gif
B. Transdermal Delivery
176
6fb6ffc4153cdc534470145c4eef46f0.gif
C. Buccal Delivery
179
6fb6ffc4153cdc534470145c4eef46f0.gif
D. Nasal Delivery
181
6fb6ffc4153cdc534470145c4eef46f0.gif
E. Pulmonary Delivery
181
6fb6ffc4153cdc534470145c4eef46f0.gif
F. Parenteral Delivery
182
6fb6ffc4153cdc534470145c4eef46f0.gif
III. Recent Successes and Future Outlook
183
6fb6ffc4153cdc534470145c4eef46f0.gif
A. Recent Significant Product Introductions
183
6fb6ffc4153cdc534470145c4eef46f0.gif
B. Future Outlook
186
6fb6ffc4153cdc534470145c4eef46f0.gif
References
192

 
< previous page page_169 next page >